This article is a correction to:
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
Sachin Chaudhary
Bhupinder Natt
Christian Bime1
Kenneth S. Knox- 1Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States
- 2Banner-University Medicine Division, Phoenix, AZ, United States
A Corrigendum on
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by Chaudhary, S., Natt, B., Bime, C., Knox, K. S., and Glassberg, M. K. (2020). Front. Med. 7:539. doi: 10.3389/fmed.2020.00539
In the published article, there was an error in affiliations for Kenneth S. Knox. Instead of having affiliations 1 and 2, Kenneth S. Knox should only have affiliation 2.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: antifibrotics, COVID - 19, ARDS, fibrosis, SARS - CoV-2, SARS, MERS (Middle East respiratory syndrome)
Citation: Chaudhary S, Natt B, Bime C, Knox KS and Glassberg MK (2021) Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. Front. Med. 7:604640. doi: 10.3389/fmed.2020.604640
Received: 10 September 2020; Accepted: 11 September 2020;
Published: 11 March 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Chaudhary, Natt, Bime, Knox and Glassberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sachin Chaudhary, sachin@deptofmed.arizona.edu